The heregulin-enriched brain parenchyma is known to promote resistance to anti-HER2 therapies enhancing the incidence of brain metastases that occurs in 50% of HER2-positive breast cancer patients [52–54]. This evidence concerns the gene ERBB2 and breast carcinoma.